Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MEN1611

Inibitore della PI3K

ONCOLOGY

Logo B-PRECISE 1611

Current development phase: Phase I/II solid tumors

preclinical
Phase I
Phase ii
Phase iii
preregistration

MEN 1611 is a phosphatidylinositol 3-kinase (PI3K) inhibitor discovered by Chugai and acquired by the Menarini Group at the end of 2016.  
PI3K is considered a critical component in the signaling pathway that regulates proliferation, differentiation and survival of tumor cells. 

MEN 1611 has been successfully tested in a phase I study for solid tumors in Europe, displaying high selectivity for class I enzyme that may lead to a differentiated profile compared to other PI3K inhibitors.

The development plan is focused on clearly defined target populations with high unmet medical need.

In 2018 the B-PRECISE-01 clinical trial, a multicenter phase Ib study to evaluate the safety and efficacy of MEN1611 plus trastuzumab with or without fulvestrant in patients with PIK3CA-mutated, HER2-positive, advanced or metastatic (a/m) breast cancer who have failed anti-HER2 based therapy, started.

Preclinical studies to strengthen the rationale for the selected indications and to support the design of  additional clinical trials are  in progress


THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more